Danaher Slips 22% This Year: Is the Masimo Acquisition the Ideal Opportunity for Investors?

Danaher Sees Equipment Order Surge Amid Acquisition

Danaher Corporation (NYSE: DHR) reported a significant 30% year-over-year growth in equipment orders in the first quarter of 2026, indicating a potential multiyear manufacturing investment cycle. The company, which focuses on life sciences and diagnostic solutions, also announced a $9.9 billion acquisition of Masimo, aiming to diversify into clinical patient monitoring technology, despite concerns over a patent dispute with Apple.

In its latest earnings statement, Danaher posted revenues of $5.95 billion, a 3% increase from the previous year, with earnings per share rising 9.8% to $1.45. The acquisition is expected to contribute an additional $0.15 to $0.20 to Danaher’s adjusted earnings per share in its first year, potentially increasing to $0.70 by the fifth year. The life sciences industry witnessed over $65 billion in mergers and acquisitions in Q1 2026, nearly doubling the total from the same period in 2025.

Despite a 22% decline in Danaher’s stock value so far this year, driven by the recent acquisition and rising debt levels, the stock is currently trading at more than 20 times forward earnings, below its historical average valuation. Investors are advised to monitor the integration of Masimo and broader market conditions that may impact the life sciences sector.